Posted by Michael Wonder on 27 Feb 2017
GSK ‘real world’ study offers new model for drug trials
27 February 2017 - Pharma groups look to evidence in normal medical settings to prove value for money.
GSK has conducted the world’s first drug trial under “real world” conditions — closely watched by an industry under greater pressure than ever to prove the value of its medicines to cost-constrained health systems.
In a global first for drug makers, GSK obtained permission to test Relvar, a drug to treat asthma and chronic obstructive pulmonary disease, before it had received full regulatory approval. It did this by setting in place an electronic patient data-monitoring system that ensured any adverse reactions were immediately communicated to physicians.
